Navigation Links
Oncolytics Biotech Inc. Announces U.S. Phase II Sarcoma Clinical Trial Conference Call
Date:11/5/2008

CALGARY, Nov. 5 /PRNewswire-FirstCall/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY), will host a conference call and webcast on Thursday, November 6, 2008 at 11:00 a.m. MT (1:00 p.m. ET) to update investors on clinical trial results in its U.S. Phase II trial for patients with bone and soft tissue sarcomas metastatic to the lung. The results are scheduled to be presented November 6, 2008 at the Chemotherapy Foundation Symposium XXVI in New York.

To access the conference call by telephone, dial 1-416-915-5651 or 1-800-732-6179. A live audio webcast will also be available at the following link: http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID=2471700, or through the Company's website at http://www.oncolyticsbiotech.com. Please connect at least 15 minutes prior to the webcast to ensure adequate time for any software download that may be needed. A replay of the webcast will be available at http://www.oncolyticsbiotech.com and will also be available by telephone through November 13, 2008. To access the telephone replay, dial 1-416-640-1917 or 1-877-289-8525 and enter reservation number 21288636 followed by the number sign.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com.

This press release c
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)..., PLYMOUTH, Mass., Nov. 9 Har...announced today that the company sponsored 48-pati... the U.S. and one site in India using the company,... to treat patients with non-reconstructable Critic...Mark D. Iafrati, M.D. Chief of Vascular Surgery at...
(Date:11/9/2009)..., WASHINGTON, Nov. 9 /PRNewswire-USNewswire/ ...e American Humanist Association, held a panel disc... controversial emerging technologies in biomedical...ed by Jonathan Moreno and Andrew Light, both of th... issues from ethical and political angles. ,, ...
(Date:11/9/2009)..., BEIJING, Nov. 9 /PRNewswire-Asia-FirstC...), ("Yongye or "the Company") a leading manufactur... plant and animal nutrient products in the,People,... will conduct a,conference call at 10:00 a.m. East...mber 16, 2009 to discuss results for the quarter e...
(Date:11/9/2009)..., SCHIEDLBERG, Austria, November 9 /PRNew...ver the world have been working on the development...rect communication channel,between the brain and a...zed,patients to communicate or to control devices ...ng the last years some patients have been supervis...
Breaking Biology Technology:Harvest Technologies Announces Completion of Patient Enrollment in its Randomized, Controlled, Double Blind Multicenter IDE Non-Reconstructable Critical Limb Ischemia Trial 2Jonathan Moreno and Andrew Light Speak About Biotechnology and Global Warming at the National Press Club 2Jonathan Moreno and Andrew Light Speak About Biotechnology and Global Warming at the National Press Club 3Yongye International Announces Conference Call to Discuss Third Quarter 2009 Results 2Yongye International Announces Conference Call to Discuss Third Quarter 2009 Results 3intendiX - Communication by Thoughts: First Patient-Ready System on the Market 2
...are flexibility , Detect Released Oligosacchari... System , Angela R. Downs Deborah A. Greer Sta...iversity, Dover, DE , We compared the Eagle Eye ... SE2000 gel imager system,for imaging Fluorophor...s. The,data generated from either system were no...
...h integrated DNA-removal step , Karen Dolter...otal RNA miniprep kit efficiently,isolates high-...,cells or 10 to 40 mg of tissue and includes an on... samples can be processed simultaneously because o...n is performed within microspin cups,which elim...
...kits target specific mutations using molecular bea...Lingyu Chen Haoqiang,Huang Jason Zhang ,Stra...ation, molecular beacons ,can distinguish human... only a,single nucleotide. We developed three si...technology, to quickly detect three common human g...
Other Biology Technology:Detect Released Oligosaccharides Using the Eagle Eye II,Still Video Imaging System 2Detect Released Oligosaccharides Using the Eagle Eye II,Still Video Imaging System 3Detect Released Oligosaccharides Using the Eagle Eye II,Still Video Imaging System 4Simple Isolation of RNA from Tissue and Cultured Cells 2Simple Isolation of RNA from Tissue and Cultured Cells 3Simple Isolation of RNA from Tissue and Cultured Cells 4Simple Isolation of RNA from Tissue and Cultured Cells 5Simple Isolation of RNA from Tissue and Cultured Cells 6Simple Isolation of RNA from Tissue and Cultured Cells 7Simple Isolation of RNA from Tissue and Cultured Cells 8Fluorescence-Based Single-Tube Assays to Rapidly Detect Human Gene Mutations 2Fluorescence-Based Single-Tube Assays to Rapidly Detect Human Gene Mutations 3Fluorescence-Based Single-Tube Assays to Rapidly Detect Human Gene Mutations 4Fluorescence-Based Single-Tube Assays to Rapidly Detect Human Gene Mutations 5Fluorescence-Based Single-Tube Assays to Rapidly Detect Human Gene Mutations 6
(Date:11/9/2009)...e for the rapid, mysterious death of phytoplankton...laborating scientists at Rutgers University and th...is same chemical may hold unexpected promise in ca...y unknown lipid, or fatty compound, in a virus tha...i , a phytoplankton that plays a major role in the...
(Date:11/9/2009)... A nutritionist whose research was instrumental i...n, Infants and Children (WIC) food subsidy will re...utstanding achievement in the field of maternal-fe...a professor in the Department of Community Health ...les School of Public Health, will receive the awar...
(Date:11/8/2009)...e loss of a gene through deletion of genetic mater...t abnormalities in learning and behavior, said a c...Medicine ( www.bcm.edu ) in a report that appears ... "This research goes about 95 percent of the way t...dividuals to this gene," said Dr. Arthur L. Beaude...
Breaking Biology News(10 mins):Newly discovered fat molecule: An undersea killer with an upside 2Newly discovered fat molecule: An undersea killer with an upside 3Newly discovered fat molecule: An undersea killer with an upside 4March of Dimes honors Dr. Gail Harrison for outstanding work in maternal-fetal nutrition 2Developmental delay could stem from nicotinic receptor deletion 2Highmark Caring Place To Honor Midstate Volunteers 48566 1Highmark Caring Place To Honor Midstate Volunteers 48566 2Highmark Caring Place To Honor Midstate Volunteers 48566 3New Phase 3 Data Continue to Indicate that Wyeths Investigational 13 valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 12578 1New Phase 3 Data Continue to Indicate that Wyeths Investigational 13 valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 12578 2New Phase 3 Data Continue to Indicate that Wyeths Investigational 13 valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 12578 3New Phase 3 Data Continue to Indicate that Wyeths Investigational 13 valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 12578 4New Phase 3 Data Continue to Indicate that Wyeths Investigational 13 valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 12578 5New Phase 3 Data Continue to Indicate that Wyeths Investigational 13 valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 12578 6PAREXEL Enhances Study Start Up and Recruitment Capabilities With Appointment of Dr Lars Olof Eriksson Formerly With Merck 48561 1PAREXEL Enhances Study Start Up and Recruitment Capabilities With Appointment of Dr Lars Olof Eriksson Formerly With Merck 48561 2PAREXEL Enhances Study Start Up and Recruitment Capabilities With Appointment of Dr Lars Olof Eriksson Formerly With Merck 48561 3PAREXEL Enhances Study Start Up and Recruitment Capabilities With Appointment of Dr Lars Olof Eriksson Formerly With Merck 48561 4PAREXEL Enhances Study Start Up and Recruitment Capabilities With Appointment of Dr Lars Olof Eriksson Formerly With Merck 48561 5
...ute of Virology and Immunology (GIVI) have identif...), a protein that acts against HIV, a finding that...fection. , The work is published today, Oct. 2, ...iences, USA. , The research, conducted by scient...Greene, MD, PhD, explains why CD4 T cells ?the imm...
...roke, paramedics, doctors, and nurses follow stand...heir efforts improve your odds for a full recovery...ction known as sepsis, which can be fatal within a...too late. , Now, a new, multicenter research cons...Shock (ProCESS), is beginning a large-scale study ...
...stem controls HIV during the earliest phases of in...sions of key immune-system molecules called HLA Cl...fragments of viral protein those molecules display...d cells. In a report in the November issue of PLO...earch Center at Massachusetts General Hospital (PA...
Other Biology News:Gladstone investigators identify a new protective action for the powerful anti-HIV factor, APOBEC3G 2New study aims to stop sepsis in its tracks 2New study aims to stop sepsis in its tracks 3Early-stage immune system control of HIV may depend on inherited factors 2Early-stage immune system control of HIV may depend on inherited factors 3
HeLa Cell Slide from ProSci, Inc
EL4 Cell Slide from ProSci, Inc
IHC Select TE Buffer pH 9.0 [Antigen/ Epitope Retrieval Reagent], 10x from CHEMICON
Hep G2 Cell Slide from ProSci, Inc
Biology Products: